ALNY

ALNYLAM PHARMACEUTICALS INC

Healthcare | Large Cap

$1.56

EPS Forecast

$1,444

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Alnylam's Third Quarter 2026: TTR Revenues Power the Pulse While Pipelines Peek Around the Corner

For ALNY, the ticker that matters is the trend. The latest Alnylam Pharmaceuticals earnings release centers on total TTR net product revenues, with EPS and earnings surprises notably absent from the headline figures in this excerpt. Still, the numbers illuminate a durable revenue engine built on AMVUTTRA and ONPATTRO, and the associated guidance and pipeline signals hint at longer-term momentum for the company and its sector peers. In market shorthand, it’s ALNY on a revenue trajectory, with EPS discussions lingering in the background as analysts model EPS consensus and consider a revenue forecast that extends beyond the current quarter.

Key Financial Highlights

The company reported a consolidated view of its third quarter ended September 30, 2026 that centers on its Total TTR (transthyretin) net product revenues. Alnylam disclosed that global net product revenues for AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) amounted to $1,130 million and $20 million, respectively, for Q3. Combined, that yields $1,150 million in total TTR net product revenues, marking 59% growth versus Q3 2025.

Within the regional breakdown, U.S. TTR net product revenues rose meaningfully, up by roughly $99 million versus the prior quarter (Q2 2026 is the comparison point referenced by the company). The growth drivers cited include stronger demand (an $81 million lift), a $17 million inventory benefit, and a modest rise in net price, with roughly $10 million in favorable gross-to-net adjustments contributing to the quarterly delta.

International TTR net product revenues also contributed to the total, rising versus Q2 2026 as launches in ATTR-CM markets like Japan, Germany, and Italy, along with timing in partner markets, provided a lift.

What Is Driving the Quarter

  • AMVUTTRA posted the lion’s share of the quarterly TTR revenue, underscoring the continued strength of the ATTR amyloidosis franchise in the US and international markets.
  • ONPATTRO contributed a smaller but still meaningful slice, highlighting diversification within Alnylam’s TTR portfolio.
  • Regional performance was bolstered by demand growth in the US and by international launches and timing in partner markets.
  • The company also signaled progress in its growth initiatives and clinical program updates that could complement the revenue base over time.

In tone and cadence, the release emphasizes progress toward longer-range goals rather than a single-quarter triumph. The narrative aligns with a strategy to grow the TTR franchise while advancing a broader pipeline that could alter the landscape of RNAi therapeutics for ATTR-CM and related indications.

Pipeline and Strategic Updates

  • TRITON-CM trial enrollment has been expanded to 2,250 patients, reinforcing a plan to position nucresiran for a potential ATTR-CM launch by 2030.
  • DML updates point to a positive trajectory for the broader RNAi platform, with optimism around data that could enable future milestones beyond the core TTR portfolio.
  • Brezosiran (ALN-HTT02) data from Phase 1 demonstrated robust target engagement and a favorable safety profile in Huntington’s disease, with a pivotal-study initiation anticipated in 2027.
  • Management reiterated confidence in achieving 2026 financial guidance, signaling discipline in execution even as it advances multiple near- and mid-term program milestones.

Implications for ALNY and Sector Peers

The Q3 2026 update reinforces a few durable themes for Alnylam and, more broadly, for the RNAi space:

  • The TTR franchise remains a credible revenue engine. The split between AMVUTTRA and ONPATTRO reflects a diversified portfolio that can cushion profit volatility in the event of slower growth in one segment.
  • International launches and partner timing matter. As Japan, Germany, and Italy push TTR adoption, the pace of international net product revenue growth could outpace US growth at times, contributing to a more balanced global profile.
  • Pipeline progression matters for long-term value. The expansion of TRITON-CM enrollment and the move toward a potential 2030 launch create a narrative of durability that investors often reward with a higher multiple, provided milestones stay on track.
  • Clinical execution and data readouts will influence competitive dynamics. Positive Phase 1 data for brezosiran in Huntington’s disease, and the expectation of a pivotal study in 2027, may broaden the company’s addressable market and attract collaboration interest, even as the core ATTR programs face competition from other modalities and partnerships.

What This Could Mean Going Forward

For ALNY, the takeaway is not a single quarter’s beat but a sustained cadence of revenue growth backed by a robust product portfolio and a pipeline that signals optionality in multiple therapeutic areas. The emphasis on gross-to-net dynamics, inventory timing, and price effects in the US hints at near-term profitability sensitivity to mix and payer environments—risks that peers in the space also confront.

If the 2030 ATTR-CM launch timeline remains intact and trial enrollments continue to convert into meaningful patient access, the company could see a multi-year boost to revenue visibility, potentially improving the EPS consensus among sell-side analysts. Conversely, any hiccup in trial timelines or a slower-than-expected uptake in international markets could compress near-term margins and recalibrate expectations for a number of sector peers who rely on late-stage pipeline milestones to justify lofty valuations.

Bottom Line

The third quarter reinforces Alnylam’s status as a revenue anchor in its niche—driven by AMVUTTRA and ONPATTRO, supported by a growing international footprint, and buoyed by a pipeline that carries both near-term milestones and long-run optionality. Analysts watching EPS expectations and revenue forecasts should note the balance of strong quarterly TTR revenues with the forward-looking milestones in nucresiran, brezosiran, and the broader RNAi platform. For sector peers, the message is clear: sustained execution in core franchises paired with disciplined capital allocation and strategic partnerships could sustain multiple expansion even as pipeline risk persists.